Working... Menu

Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03768466
Recruitment Status : Recruiting
First Posted : December 7, 2018
Last Update Posted : December 18, 2018
Information provided by (Responsible Party):
Mundipharma Korea Ltd

Brief Summary:
The purpose of this study is to evaluate the efficacy of the study drug (Targin®) after 8 weeks of treatment in patients with moderate to severe low back pain who are uncontrolled* by NSAIDs.

Condition or disease Intervention/treatment Phase
Low Back Pain Drug: Brand Name: Targin® Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 123 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: An 8-week, Prospective, Interventional, Single-arm, Multi-centre, Phase IV Study to Evaluate the Efficacy and Safety of Controlled-release Oxycodone/Naloxone (Targin®) in Moderate to Severe Low Back Pain Patients Who Are Not Adequately Controlled by NSAIDs
Actual Study Start Date : November 21, 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : April 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Back Pain

Arm Intervention/treatment
Experimental: Brand Name: Targin®
Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
Drug: Brand Name: Targin®
Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral

Primary Outcome Measures :
  1. Change of NRS average score from week 0 to week 8 [ Time Frame: week 8 ]
    reduction of pain intensity of week 8 average NRS score

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Korean patients age ≥ 19 years old
  2. Patients having moderate to severe low back pain (NRS pain score ≥4) for ≥ 7 days and ≤ 90 days not satisfactorily controlled with NSAIDs
  3. Patients showing average NRS pain score ≥4 over the last 1 week at screening point
  4. In case of previous opioids medication history, opioids wash-out period > 30 days before enrolment
  5. Patients who is willing to voluntarily sign informed consent

Exclusion Criteria:

  1. Patients with any history of hypersensitivity to oxycodone, naloxone or related products
  2. Low back pain coming from cancer, infectious disease, psychiatric issue or congenial cause
  3. Pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03768466

Layout table for location contacts
Contact: Haeri hwang, CPL 82-2-6450-9325

Layout table for location information
Korea, Republic of
Asan Medical Center Recruiting
Seoul, Korea, Republic of, 05505
Contact: Chang-Ju Hwang         
SMG-SNU Boramae Medical Center Active, not recruiting
Seoul, Korea, Republic of, 07061
Sponsors and Collaborators
Mundipharma Korea Ltd
Layout table for investigator information
Principal Investigator: JaeHyup Lee SMG-SNU Boramae Medical Center

Layout table for additonal information
Responsible Party: Mundipharma Korea Ltd Identifier: NCT03768466     History of Changes
Other Study ID Numbers: OXN18-KR-401
First Posted: December 7, 2018    Key Record Dates
Last Update Posted: December 18, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Back Pain
Low Back Pain
Neurologic Manifestations
Signs and Symptoms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists